GEO Investing

GeoTeam Looking to Trade Hemispherx Biopharma (HEB) ($0.35) on Chardan Update

The Geoteam will look to trade HEB due to Chardan Capital pitching the company as an EBOLA play with a $3 price target.

“Chardan Capital affirms its Buy rating and $3 price target on Hemispherx BioPharma (AMEXHEB) following a recent company update and expanded Ebola collaborations.”

Please note that we have little respect for Chardan due to their past involvement in financing several of what we considered to be fraudulent U.S. listed China companies. But the pump and dump momentum crowd may look at HEB, so we will give the trade shot.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.